Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma
Cytokine release syndrome (CRS) is a rare systemic inflammatory response that can be triggered by certain drugs and infections, commonly diagnosed at a disseminated stage, leading to poor prognosis. This has been well described following chimeric antigen receptor T-cell (CAR-T) therapy but has rarel...
Saved in:
Main Authors: | Erica Martel, Shijia Li, Mayssaa Hoteit, Zubin Bham |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/crh/5444075 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cytokine release syndrome
by: Esra Yildizhan, et al.
Published: (2018-12-01) -
An Excellent Clinical and Radiological Response Pattern to Pembrolizumab in a Patient With Metastatic Adrenocortical Carcinoma and Lynch Syndrome
by: Yuki Shimozawa, et al.
Published: (2025-07-01) -
Phenotypic plasticity of metastatic melanoma
by: I. N. Mikhaylova, et al.
Published: (2019-02-01) -
Metastatic anal cloacogenic cell carcinoma misdiagnosed as urothelial carcinoma with long survival
by: Burak Bilgin, et al.
Published: (2017-07-01) -
Promising Experimental Therapies for Metastatic Melanoma
by: Lam, Bao, et al.
Published: (2011)